Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 6/20 | 0.51 |
| ▸ | XIAP | P98170 | 2/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753325 | 0.83 | NR3C2 (0.74) | NR3C2XIAPBIRC2PGR | |
| SCHEMBL755954 | 0.79 | NR3C2 (0.46) | NR3C2XIAPBIRC2KMT2AELOVL6 | |
| SCHEMBL753914 | 0.79 | NR3C2 (0.46) | NR3C2XIAPBIRC2NPC1RAB9A | |
| SCHEMBL758027 | 0.79 | NR3C2 (0.39) | NR3C2XIAPBIRC2 | |
| SCHEMBL4986015 | 0.77 | NR3C2 (0.41) | NR3C2XIAPBIRC2MEN1KMT2A | |
| SCHEMBL4519278 | 0.74 | NR3C2 (0.43) | NR3C2NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL16978176 | 0.73 | NR3C2 (0.70) | NR3C2XIAPBIRC2PGR | |
| SCHEMBL20407397 | 0.71 | NR3C2 (0.74) | NR3C2XIAPBIRC2PGR | |
| SCHEMBL754718 | 0.70 | NR3C2 (0.80) | NR3C2MAPT | |
| SCHEMBL20407295 | 0.70 | NR3C2 (0.73) | NR3C2XIAPBIRC2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188073-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| CN-101379048-A | Benzo oxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-03-04 | — | — | CN | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | NR3C2 1/4885XIAP 4449/4885BIRC2 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.